Additionally, our observation of plaque-dependent increases in plasma NfL in both 3xTg-AD and 5xFAD mouse models adds further evidence for the potential use of NfL as a biomarker to monitor progression of Aβ pathology in future animal models and AD patients (de Wolf et al., 2020). This evidence concerns the gene NEFL and Alzheimer disease.